NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
申请人:AHN-GOOK PHARMACEUTICAL CO., LTD.
公开号:US20150210635A1
公开(公告)日:2015-07-30
The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.
本发明涉及一种新颖的化合物或其药物可接受的盐,该化合物抑制11β-HSD1酶活性,其制备方法,以及包含该化合物作为活性成分的药物组合物。由于本发明的化合物选择性地抑制11β-HSD1(11β-羟基类固醇脱氢酶1型)的活性,因此本发明的化合物可以有效地用作治疗由11β-HSD1过度激活引起的疾病的治疗剂,例如非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由糖皮质激素过度活动介导的疾病或状况。